FY2024 Earnings Estimate for SRPT Issued By Leerink Partnrs

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) – Research analysts at Leerink Partnrs lifted their FY2024 earnings estimates for Sarepta Therapeutics in a report released on Monday, January 20th. Leerink Partnrs analyst J. Schwartz now forecasts that the biotechnology company will post earnings per share of $3.04 for the year, up from their previous estimate of $2.46. The consensus estimate for Sarepta Therapeutics’ current full-year earnings is $2.39 per share. Leerink Partnrs also issued estimates for Sarepta Therapeutics’ Q4 2024 earnings at $2.26 EPS.

A number of other research analysts have also recently weighed in on SRPT. Cantor Fitzgerald raised shares of Sarepta Therapeutics from a “neutral” rating to an “overweight” rating and lifted their price target for the company from $152.00 to $167.00 in a research report on Thursday, November 7th. Robert W. Baird reduced their price target on shares of Sarepta Therapeutics from $200.00 to $193.00 and set an “outperform” rating on the stock in a research report on Thursday, November 7th. Royal Bank of Canada reissued an “outperform” rating and set a $182.00 target price on shares of Sarepta Therapeutics in a research report on Monday, October 21st. Evercore ISI reduced their target price on shares of Sarepta Therapeutics from $179.00 to $170.00 and set an “outperform” rating on the stock in a research report on Thursday, November 7th. Finally, Jefferies Financial Group started coverage on shares of Sarepta Therapeutics in a research report on Monday, October 21st. They set a “buy” rating and a $165.00 target price on the stock. One analyst has rated the stock with a sell rating, two have issued a hold rating, nineteen have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $178.71.

Sarepta Therapeutics Trading Up 2.6 %

Shares of SRPT stock opened at $119.14 on Wednesday. The stock has a market cap of $11.38 billion, a price-to-earnings ratio of 95.31 and a beta of 0.77. The company has a quick ratio of 3.03, a current ratio of 3.84 and a debt-to-equity ratio of 0.93. Sarepta Therapeutics has a fifty-two week low of $102.15 and a fifty-two week high of $173.25. The firm’s 50 day moving average price is $121.93 and its two-hundred day moving average price is $128.71.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in SRPT. Teachers Retirement System of The State of Kentucky bought a new stake in Sarepta Therapeutics during the second quarter worth about $4,771,000. Simplify Asset Management Inc. boosted its stake in Sarepta Therapeutics by 84.6% in the third quarter. Simplify Asset Management Inc. now owns 193,010 shares of the biotechnology company’s stock valued at $24,105,000 after acquiring an additional 88,474 shares during the last quarter. Geode Capital Management LLC boosted its stake in Sarepta Therapeutics by 2.7% in the third quarter. Geode Capital Management LLC now owns 1,696,354 shares of the biotechnology company’s stock valued at $211,910,000 after acquiring an additional 44,306 shares during the last quarter. Summit Partners Public Asset Management LLC boosted its stake in Sarepta Therapeutics by 547.9% in the third quarter. Summit Partners Public Asset Management LLC now owns 138,118 shares of the biotechnology company’s stock valued at $17,250,000 after acquiring an additional 116,800 shares during the last quarter. Finally, Larson Financial Group LLC boosted its position in shares of Sarepta Therapeutics by 1,649.8% during the third quarter. Larson Financial Group LLC now owns 8,749 shares of the biotechnology company’s stock worth $1,093,000 after purchasing an additional 8,249 shares in the last quarter. Institutional investors and hedge funds own 86.68% of the company’s stock.

Insiders Place Their Bets

In related news, Director Kathryn Jean Boor sold 1,636 shares of Sarepta Therapeutics stock in a transaction on Thursday, December 5th. The shares were sold at an average price of $125.55, for a total value of $205,399.80. Following the completion of the sale, the director now owns 5,880 shares of the company’s stock, valued at approximately $738,234. The trade was a 21.77 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of the business’s stock in a transaction on Thursday, December 12th. The stock was sold at an average price of $124.84, for a total transaction of $1,310,820.00. Following the transaction, the director now directly owns 22,840 shares of the company’s stock, valued at approximately $2,851,345.60. This represents a 31.49 % decrease in their position. The disclosure for this sale can be found here. 7.70% of the stock is currently owned by company insiders.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.